Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Working Capital Changes (2021 - 2025)

InMed Pharmaceuticals' Other Working Capital Changes history spans 5 years, with the latest figure at $444462.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 62.96% year-over-year to $444462.0; the TTM value through Dec 2025 reached -$3167.0, down 100.93%, while the annual FY2025 figure was -$173980.0, 757.72% down from the prior year.
  • Other Working Capital Changes reached $444462.0 in Q4 2025 per INM's latest filing, up from -$107412.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $637658.0 in Q4 2021 to a low of -$634410.0 in Q3 2021.
  • Average Other Working Capital Changes over 5 years is -$16051.7, with a median of -$12536.5 recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: plummeted 65268.16% in 2023, then soared 254.15% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at $637658.0 in 2021, then crashed by 99.93% to $471.0 in 2022, then plummeted by 37666.45% to -$176938.0 in 2023, then skyrocketed by 254.15% to $272743.0 in 2024, then surged by 62.96% to $444462.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Other Working Capital Changes are $444462.0 (Q4 2025), -$107412.0 (Q3 2025), and -$186125.0 (Q2 2025).